1. Quick Facts
Category: Relaxin Receptor Agonist Peptide
Risk Level: High/Experimental
Research Status: Early-Stage Experimental
Administration: Subcutaneous Injection
Typical Frequency: Daily
Estimated Half-Life: Limited Human Data Available
Primary Research Interest: Anti-Fibrotic Signaling / Tissue Remodeling
This material is provided strictly for educational and informational purposes related to peptide research and experimental signaling compounds. B7-33 is a highly experimental peptide with limited human data and incompletely characterized safety profiles. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
2. Summary
B7-33 is an experimental peptide derived from relaxin signaling research and designed to selectively activate RXFP1 (Relaxin Family Peptide Receptor 1) pathways.
Research interest in B7-33 has focused primarily on anti-fibrotic signaling, tissue remodeling, inflammation modulation, cardiovascular protection, and organ repair. Unlike native relaxin, B7-33 was engineered to preserve beneficial tissue-protective effects while providing more selective receptor activation.
What People Commonly Claim
- Powerful anti-fibrotic effects throughout the body
- Reversal of organ fibrosis
- Cardiovascular protection comparable to or better than relaxin
- Enhanced tissue remodeling and repair
- A safer and more targeted alternative to relaxin-based therapies
What the Literature Actually Shows
- B7-33 was engineered as a relaxin-derived peptide designed to selectively activate RXFP1 signaling pathways.
- Preclinical studies have demonstrated anti-fibrotic, cardioprotective, and tissue-remodeling effects in animal models.
- Most published evidence originates from laboratory and animal research rather than human clinical trials.
- Human pharmacokinetic, efficacy, and long-term safety data remain extremely limited.
- While early findings are promising, B7-33 should currently be viewed as a highly experimental research compound rather than a clinically validated therapy.
3. Reconstitution Guide
- Vial Size: 6 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2.4 mL
- Final Concentration: 2.5 mg/mL
At this concentration:
• 250 mcg = 0.10 mL (10 units)
• 500 mcg = 0.20 mL (20 units)
*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.
4. Route of Administration
B7-33 is most commonly discussed as a subcutaneous injectable peptide compound in experimental contexts.
- Primary Route: SubQ Injection
- Preferred Timing: Consistently timed daily administration
- Administration Notes: Due to limited human characterization, protocol consistency is often emphasized in experimental discussions.
5. Common Research Protocols
- Product Strength: 2.5 mg/mL
- Typical Delivered Amount: 250–500 mcg daily
- Frequency: Daily, consistently timed
- Cycle Length: 6–12 weeks on / 24 weeks off
- Special Notes: B7-33 is a synthetic relaxin-derived peptide developed to selectively activate RXFP1 signaling pathways involved in tissue remodeling and anti-fibrotic activity. Unlike many peptides discussed for performance or metabolic applications, B7-33 has primarily been investigated for fibrosis, organ protection, and tissue repair. Human data remain extremely limited, and most current knowledge originates from preclinical research. Because long-term safety remains poorly characterized, conservative cycle lengths and extended washout periods are commonly recommended.
6. Mechanism of Action
B7-33 is believed to function through selective activation of RXFP1 (Relaxin Family Peptide Receptor 1) signaling pathways.
Unlike broader relaxin signaling, B7-33 was designed to potentially isolate beneficial anti-fibrotic and tissue remodeling effects while minimizing some downstream hormonal signaling complexity.
Potential downstream mechanisms discussed in research include:
- Reduced fibrosis signaling
- Altered extracellular matrix remodeling
- Inflammation modulation
- Potential vascular effects
- Tissue repair pathway activation
7. Potential Benefits
- Potential anti-fibrotic activity
- Possible tissue remodeling support
- Inflammation modulation
- Potential cardiovascular support signaling
- Experimental tissue repair applications
8. Potential Risks / Side Effects
High/Experimental
- Limited human safety data
- Unknown long-term physiological effects
- Potential cardiovascular signaling alterations
- Hormonal pathway disruption concerns
- Injection site irritation
- Headaches
- Possible immune signaling alterations
9. Half-Life
Reliable human pharmacokinetic data for B7-33 remain extremely limited.
Most available information originates from experimental animal models and early-stage research discussions rather than large-scale clinical use.
10. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
11. Contraindications / Warnings
- Pregnancy or breastfeeding
- Cardiovascular disease
- Active autoimmune disorders
- Known hypersensitivity to peptide compounds
- Use alongside experimental hormonal therapies
12. Further Study
Overview Article
A Single-Chain Derivative of the Relaxin Hormone Is a Functionally Selective Agonist of RXFP1
The foundational paper describing the development of B7-33 and its selective RXFP1 signaling properties.
Preclinical Evidence
B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice
Demonstrates cardioprotective and anti-fibrotic effects in a myocardial infarction model and represents one of the strongest efficacy studies currently available.
Advanced Reading
The Single-Chain Relaxin Mimetic, B7-33, Maintains the Cardioprotective Effects of Relaxin and More Rapidly Reduces Left Ventricular Fibrosis Compared to Perindopril
An advanced translational study exploring the anti-fibrotic and cardioprotective potential of B7-33 relative to established therapies.
CKF Note: Interest in B7-33 is driven primarily by promising preclinical research rather than human clinical evidence. Readers should recognize that most claims regarding efficacy remain extrapolations from animal studies, and substantial evidence gaps remain regarding human safety, dosing, and long-term outcomes.
13. Research References
- PubMed
- PubMed Central (PMC)
- NIH Publications
- Relaxin signaling research literature
- Peer-reviewed fibrosis and cardiovascular journals
14. Last Reviewed
June 2026